GLYCOSYNTH LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025
PAGES FOR FILING WITH REGISTRAR
GLYCOSYNTH LIMITED
COMPANY INFORMATION
Directors
Mr M Burton
Mrs H J Turner
Mr C Turner
Mrs J Burton
Secretary
Mrs H J Turner
Company number
03139476
Registered office
14 Craven Court
Winwick Quay
Warrington
Cheshire
United Kingdom
WA2 8QU
Accountants
Fairhurst Accountants Ltd
Douglas Bank House
Wigan Lane
Wigan
Lancashire
WN1 2TB
GLYCOSYNTH LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
GLYCOSYNTH LIMITED
BALANCE SHEET
As At 30 September 2025
30 September 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
-
0
-
0
Tangible assets
3
2,531
3,236
Current assets
Stocks
7,000
7,000
Debtors
4
173,689
114,487
Cash at bank and in hand
637,249
587,659
817,938
709,146
Creditors: amounts falling due within one year
5
(546,166)
(505,031)
Net current assets
271,772
204,115
Net assets
274,303
207,351
Capital and reserves
Called up share capital
1,000
1,000
Profit and loss reserves
273,303
206,351
Total equity
274,303
207,351

For the financial year ended 30 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with section 444 of the Companies Act 2006, all of the members of the company have consented to the preparation of abridged financial statements pursuant to paragraph 1A of Schedule 1 to the Small Companies and Groups (Accounts and Directors’ Report) Regulations (SI 2008/409)(b).

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 24 April 2026 and are signed on its behalf by:
Mrs J Burton
Director
Company registration number 03139476 (England and Wales)
GLYCOSYNTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS
For The Year Ended 30 September 2025
- 2 -
1
Accounting policies
Company information

Glycosynth Limited is a private company limited by shares incorporated in England and Wales. The registered office is 14 Craven Court, Winwick Quay, Warrington, Cheshire, United Kingdom, WA2 8QU.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

1.2
Turnover

Turnover represents the net invoiced value of goods sold, excluding value added tax.

 

Royalties receivable are accounted for in the period in which they are invoiced.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
20% on reducing balance
Fixtures and fittings
20% on reducing balance
Computers
33% on cost
Motor vehicles
20% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

1.5
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

GLYCOSYNTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
For The Year Ended 30 September 2025
1
Accounting policies
(Continued)
- 3 -
Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.7
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.8
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

GLYCOSYNTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
For The Year Ended 30 September 2025
- 4 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
13
13
3
Tangible fixed assets
Plant and equipment
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
£
Cost
At 1 October 2024 and 30 September 2025
18,718
25,249
8,829
2,800
55,596
Depreciation and impairment
At 1 October 2024
17,248
24,640
8,829
1,643
52,360
Depreciation charged in the year
294
122
-
0
289
705
At 30 September 2025
17,542
24,762
8,829
1,932
53,065
Carrying amount
At 30 September 2025
1,176
487
-
0
868
2,531
At 30 September 2024
1,470
609
-
0
1,157
3,236
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
169,735
110,488
Other debtors
3,954
3,999
173,689
114,487
5
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
13,521
58,436
Taxation and social security
107,187
103,524
Other creditors
425,458
343,071
546,166
505,031
GLYCOSYNTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
For The Year Ended 30 September 2025
- 5 -
6
Parent company

The company is controlled by Mr & Mrs Burton by virtue of their shareholding.

2025-09-302024-10-01falsefalsefalse30 April 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityMr M BurtonMr C TurnerMrs J BurtonMrs J BurtonMrs H J Turner031394762024-10-012025-09-3003139476bus:Director12024-10-012025-09-3003139476bus:CompanySecretaryDirector12024-10-012025-09-3003139476bus:Director22024-10-012025-09-3003139476bus:Director32024-10-012025-09-3003139476bus:CompanySecretary12024-10-012025-09-3003139476bus:Director42024-10-012025-09-3003139476bus:RegisteredOffice2024-10-012025-09-30031394762025-09-30031394762024-09-3003139476core:PlantMachinery2025-09-3003139476core:FurnitureFittings2025-09-3003139476core:ComputerEquipment2025-09-3003139476core:MotorVehicles2025-09-3003139476core:PlantMachinery2024-09-3003139476core:FurnitureFittings2024-09-3003139476core:ComputerEquipment2024-09-3003139476core:MotorVehicles2024-09-3003139476core:CurrentFinancialInstrumentscore:WithinOneYear2025-09-3003139476core:CurrentFinancialInstrumentscore:WithinOneYear2024-09-3003139476core:CurrentFinancialInstruments2025-09-3003139476core:CurrentFinancialInstruments2024-09-3003139476core:ShareCapital2025-09-3003139476core:ShareCapital2024-09-3003139476core:RetainedEarningsAccumulatedLosses2025-09-3003139476core:RetainedEarningsAccumulatedLosses2024-09-3003139476core:PlantMachinery2024-10-012025-09-3003139476core:FurnitureFittings2024-10-012025-09-3003139476core:ComputerEquipment2024-10-012025-09-3003139476core:MotorVehicles2024-10-012025-09-30031394762023-10-012024-09-3003139476core:PlantMachinery2024-09-3003139476core:FurnitureFittings2024-09-3003139476core:ComputerEquipment2024-09-3003139476core:MotorVehicles2024-09-30031394762024-09-3003139476bus:PrivateLimitedCompanyLtd2024-10-012025-09-3003139476bus:SmallCompaniesRegimeForAccounts2024-10-012025-09-3003139476bus:FRS1022024-10-012025-09-3003139476bus:AuditExemptWithAccountantsReport2024-10-012025-09-3003139476bus:FullAccounts2024-10-012025-09-30xbrli:purexbrli:sharesiso4217:GBP